Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06945484

PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study

This study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage II-III primary lung cancer patients receiving multimodal therapy, and delivered through telehealth.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Texas Medical Branch at Galveston, Galveston, Texas, United States

Loading trial locations.

About this study

This is a pilot study evaluating the feasibility of the Precision Exercise Regimen for Cancer Care (PERCC) intervention in stage II and stage III Non-Small Cell Lung Cancer (NSCLC) patients receiving multimodal therapy at the Huntsman Cancer Institute (HCI) at the University of Utah. Eligible patients will begin the intervention at the pre-treatment clinic visit and continue until approximately two months post-surgery.

The PERCC intervention is a virtually supervised home-based exercise program. Participants will engage in exercise starting at least two weeks before receiving their first neoadjuvant treatment for lung cancer and continuing until two months after receiving surgical treatment. The exercise modes will include basic transfer and calisthenics mobility, aerobic, and resistance exercises and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 18 and older at time of diagnosis
  • Patient diagnosed with stage II and III non-small cell lung cancer (NSCLC)
  • Patient receives either neoadjuvant chemotherapy or immunotherapy and surgery
  • Patient able to follow direction and complete questionnaires in English or Spanish
  • Patient agrees to complete the PERCC intervention

Exclusion criteria

  • Morbidly obese (BMI >40 kg/m2 ) or anorexic (BMI <17.5 kg/m2 )
  • Abnormalities on screening physical exam per study physicians or physical therapist to contraindicate participation in exercise program compliance
  • Alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer)
  • Patient scheduled to receive single modality cancer treatment (unimodal therapy), scheduled to begin treatment within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started

Treatment and study plan

Precision Exercise Regimen for Cancer Care (PERCC)

Other

PERCC has exercise modes including basic transfer and calisthenics mobility, aerobic, and resistance exercises, and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting). Each participant will complete one supervised, home-based exercise training session per week, delivered through telehealth, that will focus on the resistance exercise prescription. Other unsupervised exercise training sessions will focus on the aerobic exercise prescription and will be completed individually

Primary outcomes

  1. Feasibility - Recruitment and Retention

    Time frame: up to two months post-surgery

    Feasibility of the PERCC intervention will be evaluated by our ability to recruit and retain the needed number of patients with 80% exercise intervention attendance.

Secondary outcomes

  1. Feasibility - Safety

    Time frame: up to two months post-surgery

    The feasibility of the PERCC intervention will be evaluated based on participant safety.

    This outcome measure will assess the safety and tolerability of the study treatment.

    The severity of AEs will be assessed using CTCAE v5.0 criteria, a 1-5 scale with higher numbers indicating greater severity. Grade 1 indicates "mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated" and Grade 5 indicates "death related to AE".

    Subjects will be monitored for adverse events from the start of treatment until two months post-surgery.

Study contacts

Contact information is provided by the study sponsor or research team.

Cornelia Ulrich, MS, PhD

CONTACT

[email protected]

801-213-5716

Thomas Varghese, MD, MS, MBA, FACS

CONTACT

[email protected]

801-581-5311

Sponsors and collaborators

Lead sponsor

University of Utah

Other

Registry information

Acronym: PILOT PERCC

Important dates

Study start
2025
Primary completion
2027
Study completion
2030
First posted
Apr 25, 2025
Registry last updated
Feb 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.